KRAS and neoplasm: We found the extent of CDK1 phosphorylation at Thr161 to be enhanced in KRAS mutant cells compared to WT cells in the SW48 KRAS isogenic model, PDAC and CRC non-isogenic tumour cell lines (Fig 6A–6C and S6 and S7 Figs).